# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $5$ 807.92)

SEP 1.1 2012

A. 510(k)Number: K112221   
B. Purpose for Submission: New device   
C. Measurand: Anti-SLA/LP autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay

E. Applicant: EUROIMMUN US INC.

F. Proprietary and Established Names: EUROIMMUN Anti-SLALP ELISA (igG)

G. Regulatory Information:

1. Requlation: 21 CFR 866.5660 - Multiple autoantibodies immunological test system   
2. Classification: Class II   
3. Product code: NIY   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-SLALP ELISA (IgG) test kit is intended for the qualitative detection of IgG class autoantibodies against SLALP in human serum and plasma. It is used as an aid in the diagnosis of autoimmune hepatitis, type 1, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

# I. Device Description:

The EUROIMMUN Anti-SLALP ELISA (IgG) consists of a microwell ELISA plate coated with SLALP antigen, calibrator positiveand negative control, peroxidase-abelled anti-human IgG conjugate, samplebuff wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite SLA ELISA   
2. Predicate 510(k) number(s):. K021482   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to SLA/LP* as an aid indiagnosis of autoimmune hepatitis.</td><td rowspan=1 colspan=1>Detection of IgG antibodies to SLA* as an aid indiagnosis of autoimmune hepatitis.</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Recombinant SLA/LP* antigen</td><td rowspan=1 colspan=1>Recombinant SLA* antigen</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Rabbit anti-human IgG labeled with horseradishperoxidase</td><td rowspan=1 colspan=1>Goat anti-human IgG labeled with horseradishperoxidase</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive, 1 negativeir:</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types anddilution</td><td rowspan=1 colspan=1>Serum or plasma1:101 dilution</td><td rowspan=1 colspan=1>Serum1:101 dilution</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>25 Units</td></tr></table>

recommendation. 1510-15.

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

Patient samples are diluted 1:101 in sample buffer, $1 0 0 ~ \mu \mu$ of each diluted patient sample and pre-diluted controls and calibratorae added  theantigen coatedmicrotiter wells and incubated or 30minutes t ro temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 \mu |$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter wel. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with 300 ul of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \mu \mu$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 \mu |$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and $6 5 0 \mathsf { n m }$ within 30 minutes.

# M. Performance Characteristics (where applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Threproduciblityof the test was investigated with samples at dfferent pointson he caliatin curve. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 24 determinations performed in 6 different runs (days) according to the package insert. Both intra-assay and inter-assay reproducibility were found to be sufficient as no positive sample was found negative and vice versa. The following results were obtained:

Intra-assay reproducibility

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=8>. Anti-SLA/LP ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.2-0.2</td><td rowspan=1 colspan=1>0.4 - 0.4</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.1 -1.2</td><td rowspan=1 colspan=1>1.1 - 1.4</td><td rowspan=1 colspan=1>1.5-1.7</td><td rowspan=1 colspan=1>3.4- 3.7</td><td rowspan=1 colspan=1>4.6 - 5.3</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

# Inter-assay reproducibility

<table><tr><td rowspan=2 colspan=1>n = 24</td><td rowspan=1 colspan=8>Anti-SLA/LP ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.2-0.3</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.0 - 1.3</td><td rowspan=1 colspan=1>1.0 -1.3</td><td rowspan=1 colspan=1>1.6-1.8</td><td rowspan=1 colspan=1>3.4- 4.2</td><td rowspan=1 colspan=1>4.7-5.8</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>neg</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=1>pos</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

The Lot to Lot reproducibiliy was investigatedduring the validaton and quality control of the ki using different lots with QC samples distributed over the measurement range. Lot to lot reproducibility was found to be sufficient as no positive sample was found negative and vice versa. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=8>Anti-SLA/LP ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=2>Sample 1</td><td rowspan=1 colspan=2>Sample 2</td><td rowspan=1 colspan=2>Sample 3</td><td rowspan=1 colspan=2>Sample 4</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=2>6*</td><td rowspan=1 colspan=2>6*</td><td rowspan=1 colspan=2>6*</td><td rowspan=1 colspan=2>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=2>5.6</td><td rowspan=1 colspan=2>7.6</td><td rowspan=1 colspan=2>9.7</td><td rowspan=1 colspan=2>0.9</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=2>5.4-6.0</td><td rowspan=1 colspan=2>7.3-8.0</td><td rowspan=1 colspan=2>9.5- 9.9</td><td rowspan=1 colspan=2>0.9-0.9</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=2>pos</td><td rowspan=1 colspan=2>pos</td><td rowspan=1 colspan=2>pos</td><td rowspan=1 colspan=2>pos</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=2>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=2>0%</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=8>Anti-SLA/LP ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=2>Sample 6</td><td rowspan=1 colspan=2>Sample 7</td><td rowspan=1 colspan=2>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>38**</td><td rowspan=1 colspan=2>38**</td><td rowspan=1 colspan=2>16**</td><td rowspan=1 colspan=2>10**</td><td rowspan=1 colspan=1>10**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=2>3.9</td><td rowspan=1 colspan=2>0.1</td><td rowspan=1 colspan=2>0.1</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>2.1- 4.1</td><td rowspan=1 colspan=2>3.2-4.6</td><td rowspan=1 colspan=2>0.1 - 0.2</td><td rowspan=1 colspan=2>0.1-0.2</td><td rowspan=1 colspan=1>0.1-0.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>pos</td><td rowspan=1 colspan=2>pos</td><td rowspan=1 colspan=2>neg</td><td rowspan=1 colspan=2>neg</td><td rowspan=1 colspan=1>neg</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.   
C. Traceability, Stability, Expected values (controls, calibrators or methods): There is no recognized standard or reference material for anti-SLA/LP antibodies. Results are given as ratios.

d. Limit of detection: Not applicable.

e. Analytical specificity:

Cross-reactivity: The quality of the antigen used and the antigen source ensure a high specificity of the ELISA. Cross reactivity was investigated using a panel of 18 sera serologically positive for antibodies against LKM. Al 18 sera were negative in the Anti-SLALP ELISA (IgG), so no cross reactivity is expected.

Interference: To investigate the influence from hemoglobin, triglycerides and bilirubin, 5 different specimens at different anti-SLA/LP concentrations (ratio $0 . 4 \ : - \ : 1 0 . 0 )$ were spiked with potential interfering substances and were incubated with the test system. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 0 \mathrm { ~ - ~ } 1 1 9 \%$ . No significant interference was observed for concentrations of up to 1000 mg/dl for hemoglobin, 2000 mg/dl for triglyceride and 40 mg/dl for bilirubin.

f. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device:

A study was performed in cooperation with a university clinical hospital comparing the performance of the EUROiMMUN Anti- SLA/LP ELISA (IgG) and an FDA released predicate device. 167 samples were investigated (58 from AIH patients, 66 from PBC patients, 15 from patients with AiH/PBC overlap syndrome and 28 from patients with viral hepatitis). The panel consisted of 30 men and 137 women. Age ranged from 1 to 87 years with an average age of 50 years. To cover the lower range with more samples, additional 23 samples were created by mixing of positive and negative samples. Borderline samples were considered for positive agreement.

<table><tr><td colspan="4">n = 190</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4"></td><td colspan="3">positive borderline</td><td>negative</td></tr><tr><td rowspan="2">EUROIMMUN Anti-SLA/LP ELISA (IgG)</td><td colspan="3">positive</td><td colspan="2">30</td><td colspan="2">1</td></tr><tr><td colspan="3">negative</td><td colspan="2">0</td><td colspan="2">5 154</td></tr><tr><td></td><td></td><td>159</td><td></td><td colspan="2">95% C.I.:</td><td>0</td><td>99.0%</td></tr><tr><td>Negative agreement</td><td>154 /</td><td></td><td>=</td><td colspan="2">96.9%</td><td>92.8%</td><td></td></tr><tr><td>Positive agreement Overall agreement</td><td>31 1 185 1</td><td>31 190</td><td>= =</td><td colspan="2">100.0% 95% C.I.: 97.4% 95% C.I.:</td><td>88.8% 94.0%</td><td>100.0% 99.1%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using 16 sample pairs each of serum and corresponding plasma. The samples cover concentrations in the diagnostically important range and the cut-off. Passing-Bablok regression was calculated for the comparison of serum to plasma. The results are shown in the table below.

<table><tr><td></td><td>EDTA plasma</td><td>Heparin plasma</td><td>Citrate plasma</td></tr><tr><td>Regression equation (y = plasma, x = serum)</td><td>y = -0.02 + 1.00 x</td><td>y = 0.02 + 1.00 x</td><td>y = 0.04 + 0.99 x</td></tr><tr><td>95% C.I. of intercept</td><td>-0.14 to 0.18</td><td>-0.06 to 0.21</td><td>-0.18 to 0.16</td></tr><tr><td>95% C.I. of slope</td><td>0.94 to 1.06</td><td>0.94 to 1.03</td><td>0.94 to 1.05</td></tr></table>

A comparison in which the $9 5 \%$ C.I. of the slope contains 1.0 and the $9 5 \%$ C.I. of the intercep1 contains 0 indicates equivalence of concentration between serum and the corresponding plasma matrices. The comparisons above satisfy this condition.

Coefficients of determination were found to be above 0.99 and %BlAS from serum was in the range of 88 to $120 \%$ (serum $= 1 0 0 \%$ ti

Clinical studies:

In a clinical study, performed in cooperation with several university,hospital and privatelaboratoris,n total 515 clinically characterized samples (65 from AlH-1 patients, 68 from AlH-2 patients, 15 from patiens with AlH/PBC overlap syndrome and 367 from other control groups) were investigated for anti-SLALP antibodies (IgG). The EUROIMMUN Anti-SLALP ELISA (IgG) showed a sensitivity for AIH type 1 of EY $2 7 . 7 \%$ $( 9 5 \%$ c.i.: $1 7 . 3 - 4 0 . 2 \%$ The specificity was $100 . 0 \%$ $( 9 5 \%$ C.I.: $9 9 . 2 \mathrm { ~ - ~ } 1 0 0 . 0 \% )$ without the AIH/PBC overlap samples; specificity was $9 9 . 3 \%$ $9 5 \%$ C.I.: $9 8 . 1 \mathrm { ~ - ~ } 1 0 0 \%$ when these samples were included.

a Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.1.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Autoimmune hepatitis type 1 (AlH-1)</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>27.7%</td><td rowspan=1 colspan=1>17.3-40.2%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Anti-SLA/LP ELISA (IgG)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>AlH/PBC overlap syndrome</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>51.9-95.7%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Autoimmune hepatitis type 2 (AlH-2)</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>91.0 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Viral hepatitis</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.9- 100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Toxic liver damages</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>76.8- 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Steatohepatitis</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>85.8- 100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Primary biliary liver cirrhosis (PBC)</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.7 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Primary sclerosing cholangiitis (PSC)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>82.4-100.0%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.5- 100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total (without panel 2)</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>99.2 - 100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total (including panel 2)</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>447</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>98.1 - 99.9%</td></tr></table>

C. \*from the following groups: MCTD $( \bar { \boldsymbol { \mathsf { n } } } = 2 0 )$ , celiac disease $( \mathsf { n } = 1 \mathsf { 1 } )$ ), Diabetes Type I $( \mathsf { n } = 1 2 )$ , Hashimoto $( n = 1 1$ , Grave's disease $( n = 1 2 )$ , ulcerative colitis $( n = 1 5 )$ d. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-SLALP antibodies (IgG) were analyzed with the EUROIMMUN Anti-SLALP ELISA (gG in a panel of 150 apparently healthy blood donors (mixed age and sex). With a cut-off of ratio 1.0, all blood donors were found negative.

<table><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>Ratio 0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>Ratio 0.8</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>Ratio 0.1</td></tr><tr><td rowspan=1 colspan=1>Std dev. (SD)</td><td rowspan=1 colspan=1>Ratio 0.11</td></tr><tr><td rowspan=1 colspan=1>95th percentile</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>99th percentile</td><td rowspan=1 colspan=1>0.6</td></tr></table>

V. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

EUROIMMUN US, Inc. c/o Ms. Kathryn Kohl Managing Director 1 100 The American Road Morris Plains, NJ 07950

Re: k112221 Trade/Device Name: EUROIMMUN Anti-SLA/LP (IgG) Regulation Number: 21 CFR $\ S 8 6 6 . 5 6 6 0$ Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: II Product Code: NIY Dated: September 5, 2012 Received: September 7, 2012

Dear Ms. Kohl:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/cb9a90bded5b6ac17db955dfbae74a44ce8c1561689ab28be677d7864587c12d.jpg)

n Maria Chan, Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K112221

Device Name: Anti-SLA/LP ELISA (IgG)

Indications For Use:

The EUROlMMUN Anti-SLA/LP ELISA (IgG) test kit is intended for the qualitative detection of IgG class autoantibodies against SLAVLP (soluble liver antigen/liverpancreas antigen) in human serum and plasma. It is used as an aid in the diagnosis of autoimmune hepatitis, type 1, in conjunction with other laboratory and clinical findings.

Prescription UseX AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/7a3a369992ca27edb59a656c6ff31300285ce3f9b8f7ae3ffa633094cee01166.jpg)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety 510K K112221